Phenomenology and Course of Alcoholic Hallucinosis
Overview
Affiliations
The objective of the study was to examine the correlates, phenomenology, and short-term treatment response to benzodiazepines and antipsychotics in an inpatient sample with alcohol-induced psychotic disorder, predominant hallucinations i.e., F10.52. We reviewed the charts of the patients admitted in a tertiary care addiction treatment center between 2010 and 2016 with the diagnosis of alcoholic hallucinosis. Among 6,493 patients admitted with alcohol dependence during the study period, 61 patients (0.9%) had alcoholic hallucinosis. Among them, 41 (67.2%) had alcoholic hallucinosis in the past; 26 (42.6%) had a family history of psychosis. Only auditory hallucinations were found in 46 patients (75.4%), only visual hallucinations in 3 patients (5%), and both auditory and visual hallucinations in 12 (19.7%). Thirty-four (55.7%) had delusions, which were secondary to hallucinations. Suicidality which includes suicidal ideas and attempts was noted in 12 (19.7%) patients. Fifty-three (86.9%) patients had hallucinations exclusively during alcohol withdrawal, while 8 (13.1%) had them during withdrawal as well as while consuming alcohol. At the end of six months, 13.1% of the patients had an independent psychotic disorder diagnosed. The primary mode of management was treatment with only benzodiazepines ( = 37, 60.7%) or benzodiazepines and antipsychotics ( = 24, 39.3%). The reasons for starting antipsychotics were the presence of florid psychotic symptoms (26.2%) and incomplete symptom resolution with benzodiazepines (9.8%). The median duration of response was four days, with 25th to 75th quartile range at two to seven days. Alcoholic hallucinosis is an acute short-lasting psychotic disorder which lasts for less than a week when treated. Suicidality is high in this group, which needs attention. Benzodiazepines as part of withdrawal management may be sufficient for a majority of cases. Antipsychotics may be required in selected cases. A high degree of recurrence and morbidity indicates a need to intervene early with an abstinence-oriented management goal.
Alcohol use disorder research in India: An update.
Narasimha V, Mukherjee D, Arya S, Parmar A Indian J Psychiatry. 2024; 66(6):495-515.
PMID: 39100372 PMC: 11293778. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_758_23.
Minimizing policy-biased appraisals of the evidence on cannabis and psychosis.
Hall W Front Psychiatry. 2023; 13:1047860.
PMID: 36699475 PMC: 9868569. DOI: 10.3389/fpsyt.2022.1047860.
Skryabin V, Zastrozhin M, Parkhomenko A, Lauschke V, Smirnov V, Petukhov A Curr Drug Metab. 2022; 23(13):1067-1071.
PMID: 36579390 DOI: 10.2174/1389200224666221228112643.
Charles Bonnet Syndrome in the Setting of a Traumatic Brain Injury.
Irizarry R, Sosa Gomez A, Tamayo Acosta J, Gonzalez Diaz L Cureus. 2022; 14(9):e29293.
PMID: 36147864 PMC: 9482793. DOI: 10.7759/cureus.29293.
Parkhomenko A, Zastrozhin M, Skryabin V, Ivanchenko V, Pozdniakov S, Noskov V Psychopharmacol Bull. 2022; 52(3):58-67.
PMID: 35815171 PMC: 9235315.